Immunovia completes validation of next-gen pancreatic cancer test, launching large-scale clinical study.

Immunovia has successfully completed analytical validation of its next-generation test for early-stage pancreatic cancer, demonstrating strong performance metrics such as precision and sensitivity. The validation utilized an automated ELISA analyzer, improving efficiency over prior methods. The company has launched a large-scale clinical study to further evaluate the test's accuracy for detecting stage 1 and 2 pancreatic cancer, with results anticipated by December 2024.

October 02, 2024
3 Articles